Myeloma Paper of the Day, October 12th, suggested by Robert Orlowski

Robert Orlowski shared a post on X:

“Myeloma Paper of the Day: Pharmacovigilance study of cardiovascular AEs associated with targeted therapies for myeloma finds significant disproportionality for daratumumab, elotuzumab, and isatuximab with AE risk higher in 1st month and again after 1 year.”

“Cardiovascular adverse events associated with targeted therapies for multiple myeloma: a pharmacovigilance study”

Authors: Yanli Zhang, Chang Shan, Xinxin Zhang, Ying Liu, Yunlong Xia, Yanfeng Wang.

Other posts featuring Robert Orlowski on OncoDaily.

Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas, MD Anderson Cancer Center including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.

Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.

Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response.

Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.